Velcade [bortezomib], thalidomide, dexamethasone (VTD) induction therapy followed by melphalan, prednisone, thalidomide (MPT) maintenance as a first line treatment for the patients with multiple myeloma who are non-transplant candidates

Trial Profile

Velcade [bortezomib], thalidomide, dexamethasone (VTD) induction therapy followed by melphalan, prednisone, thalidomide (MPT) maintenance as a first line treatment for the patients with multiple myeloma who are non-transplant candidates

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Bortezomib; Dexamethasone; Melphalan; Prednisone; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top